Clinical Trial Update: IBI310 in Combination with Sintilimab in Patients with DNA Mismatch Repair Deficient (dMMR)/microsatellite Instability High (MSI-H) Locally-advanced or Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of IBI310 and sintilimab in DNA mismatch repair–deficient/MSI-H colorectal cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• IBI310 (IBI310)
• Sintilimab (sintilimab)

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Colorectal Cancer | Phase 2 | Status: TERMINATED